[Everolimus: immunosuppression with antilymphoproliferative therapy].
Pascual
J
J
Servicio de Nefrología, Hospital Ramón y Cajal, Madrid. jpascual.hrc@salud.madrid.org
D000328:Adult; D000818:Animals; D002648:Child; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D000068338:Everolimus; D006084:Graft Rejection / Q000188:drug therapy / Q000517:prevention & control; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects; D015337:Multicenter Studies as Topic; D016377:Organ Transplantation; D011323:Primates; D051381:Rats; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D022061:Tacrolimus Binding Protein 1A / Q000378:metabolism; D014184:Transplantation, Homologous / Q000276:immunology
D007166:Immunosuppressive Agents; D000068338:Everolimus; D022061:Tacrolimus Binding Protein 1A; D020123:Sirolimus